Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Probiotix Health PLC - Result of Requisitioned General Meeting | 4 | RNS | ||
18.10. | OptiBiotix Health - Response to Publication of Circular by ProBiotix | 1 | RNS | ||
10.10. | Probiotix Health touts new deal with Mexico-based Raff for LPLDL | 3 | Alliance News | ||
10.10. | Probiotix Health PLC - New Commercial Partnership in Mexico | 1 | RNS | ||
09.10. | ProBiotix Health posts strong performance as US sales improve | 2 | Alliance News | ||
08.10. | Probiotix Health PLC - Q3 2024 Trading Update | 1 | RNS | ||
03.10. | Probiotix Health PLC - New Commercial Partnership in Ukraine | - | RNS | ||
26.09. | IN BRIEF: ProBiotix Health and shareholder OptiBiotix continue spat | 2 | Alliance News | ||
26.09. | OptiBiotix Health - Response to Probiotix Health requisition notice | 2 | RNS | ||
16.09. | Probiotix Health PLC - New Commercial Partnership in Greece | 1 | RNS | ||
06.09. | ProBiotix says fundraise valid after shareholder OptiBiotix hits out | 2 | Alliance News | ||
05.09. | OptiBiotix Health - ProBiotix Health plc Fundraise | 2 | RNS | ||
04.09. | Probiotix Health PLC - Share Subscription and Proposed Board Appointment | - | RNS | ||
30.08. | EARNINGS: ProBiotix Health hails positive outlook as revenue surges | 2 | Alliance News | ||
30.08. | Probiotix Health PLC - Half-year Report | - | RNS | ||
15.08. | IN BRIEF: ProBiotix Health enters sales agreement with DanCare Health | 2 | Alliance News | ||
15.08. | Probiotix Health PLC - New commercial partnership agreement in China | 1 | RNS | ||
08.08. | Probiotix Health PLC - Result of AGM | - | RNS | ||
29.07. | Probiotix Health PLC - New appointment | - | RNS | ||
15.07. | Probiotix Health PLC - Six month trading update | - | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BRAIN BIOTECH | 2,700 | +1,50 % | EQS-Adhoc: BRAIN Biotech AG: BRAIN Biotech schließt exklusiven Pharma-Lizenzvertrag für G-dase E® CRISPR-Cas-Technologie mit Akribion Therapeutics GmbH über bis zu 92,3 Mio. Euro Meilensteinzahlungen plus Lizenzgebühren ab | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Vertrag
BRAIN Biotech AG schließt exklusiven Pharma-Lizenzvertrag für G-dase E® CRISPR-Cas-Technologie mit Akribion Therapeutics GmbH... ► Artikel lesen | |
MUSTGROW BIOLOGICS | 1,240 | -1,59 % | Mustgrow Biologics CEO Corey Giasson interview at Cantech 24 | ||
OPTIBIOTIX HEALTH | 0,120 | +2,56 % | OptiBiotix Health - Requisition update | ||
EVOTEC | 8,100 | +13,37 % | Evotec Aktie: Wochen der Wahrheit? | Bei der Evotec Aktie haben am Donnerstag und Freitag zum einen Gewinnmitnahmen nach dem jüngsten Kursanstieg das Bild geprägt. Aber - zumindest am Donnerstag - blieben zudem Rückkäufe der Evotec Aktie... ► Artikel lesen | |
QIAGEN | 40,170 | +1,11 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
VIKING THERAPEUTICS | 58,46 | -14,18 % | AKTIONÄR-Depotwert Gubra: Bald wie Viking Therapeutics? | Die Aktie von Viking Therapeutics hat in der Vorwoche massive Kursgewinne verzeichnet. Vor allem die Aussicht auf weiteren Studiendaten zum Adipositas-Hoffnungsträger VK2735 Anfang November sowie die... ► Artikel lesen | |
BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
ADMA BIOLOGICS | 19,300 | +0,29 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
DISC MEDICINE | 59,50 | +28,37 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,55 | -0,22 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,000 | +7,58 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,040 | -0,24 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,990 | +6,86 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
DYNE THERAPEUTICS | 28,870 | +0,21 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
ARCELLX | 87,83 | +2,59 % | Arcellx (ACLX) Surged in Q3. Here's Why |